The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. The Novor team is thrilled to be part of this event from April 1-5, 2017 at the Walter E. Washington Convention Center, Washington, D.C.
Antibodies are widely used in cancer research and treatment. Rapid Novor provides the technologies and service to directly sequence any antibody protein without the need accessing the cell line. Our Antibody Protein Sequencing Service has helped many companies and research labs around world to retrieve the sequence information accurately and quickly. In the past year alone, we have successfully sequenced over a hundred antibodies. Those are the cases tested by our customers that the expressed antibodies behave similarly to the original ones.
We invite you for a chat at our booth #1166 and see how we may help in your cancer research.
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics